All In Biotech

Drug Trial Radar · NCT02792231

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Last checked: Nov 20, 2026Latest source record: Nov 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 955 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

955

Actual

Start

Aug 26, 2016

Primary completion

Jul 10, 2019

Study completion Oct 22, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

Conditions

  • Relapsing Multiple Scelrosis

Interventions

  • Ofatumumab subcutaneous injectionDrug

    Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter

  • Teriflunomide-matching placebo capsulesDrug

    Placebo capsule, matching in appearance to teriflunomide, taken orally once daily

  • Teriflunomide capsuleDrug

    Teriflunomide 14 mg oral capsule taken once daily

  • Matching placebo of ofatumumab subcutaneous injectionsDrug

    Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Baseline up to 2.5 years

Locations

178 sites in 30 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Cullman, Alabama

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Basalt, Colorado

  • Novartis Investigative Site

    Boulder, Colorado

  • Novartis Investigative Site

    Centennial, Colorado

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Fairfield, Connecticut

  • Novartis Investigative Site

    Newark, Delaware

  • Novartis Investigative Site

    Bradenton, Florida

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Maitland, Florida

  • Novartis Investigative Site

    Ocala, Florida

  • Novartis Investigative Site

    Oldsmar, Florida

  • Novartis Investigative Site

    Ormond Beach, Florida

  • Novartis Investigative Site

    Palm Coast, Florida

  • Novartis Investigative Site

    Sarasota, Florida

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Suwanee, Georgia

  • Novartis Investigative Site

    Anderson, Indiana

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Wellesley, Massachusetts

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Golden Valley, Minnesota

  • Novartis Investigative Site

    Billings, Montana

  • Novartis Investigative Site

    Great Falls, Montana

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    Asheville, North Carolina

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Greensboro, North Carolina

  • Novartis Investigative Site

    Akron, Ohio

  • Novartis Investigative Site

    Columbus, Ohio

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.